231 related articles for article (PubMed ID: 1751578)
1. Prognostic factors in Hodgkin's and non-Hodgkin's lymphomas.
Coiffier B
Curr Opin Oncol; 1991 Oct; 3(5):843-51. PubMed ID: 1751578
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.
Sanna G; Lorizzo K; Rotmensz N; Bagnardi V; Cinieri S; Colleoni M; Nolè F; Goldhirsch A
Ann Oncol; 2007 Feb; 18(2):288-92. PubMed ID: 17088328
[TBL] [Abstract][Full Text] [Related]
3. Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.
Low SE; Horsman JM; Walters SJ; Hancock H; Smith P; Linch D; Hancock BW
Br J Haematol; 2003 Jan; 120(2):277-80. PubMed ID: 12542487
[TBL] [Abstract][Full Text] [Related]
4. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
[TBL] [Abstract][Full Text] [Related]
5. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin's and non-Hodgkin's lymphomas.
McElwain TJ
Br J Hosp Med; 1984 Jan; 31(1):10-4, 18-9. PubMed ID: 6697038
[No Abstract] [Full Text] [Related]
8. Clinicopathologic features and prognostic factors of primary extranodal non-Hodgkin's lymphomas in Turkey.
Arican A; Dinçol D; Akbulut H; Onur H; Demirkazik A; Cay F; Içli F
Am J Clin Oncol; 1999 Dec; 22(6):587-92. PubMed ID: 10597743
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
Urquhart A; Berg R
Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
[TBL] [Abstract][Full Text] [Related]
11. [Malignant lymphoma: a study of an outpatient cohort].
Burla M; Egli F; Rhyner K
Schweiz Rundsch Med Prax; 1990 Jan; 79(5):101-10. PubMed ID: 2305142
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors in Hodgkin and non-Hodgkin lymphomas].
Cuenca X; Xhaard A; Mounier N
Bull Cancer; 2009 Apr; 96(4):461-73. PubMed ID: 19357020
[TBL] [Abstract][Full Text] [Related]
13. [Long-term follow-up of Hodgkin's disease and unfavorable type of non-Hodgkin's lymphoma].
Sampi K; Maseki N; Sakurai M; Hattori M
Rinsho Ketsueki; 1988 Feb; 29(2):144-8. PubMed ID: 3385941
[No Abstract] [Full Text] [Related]
14. Haptoglobin-related protein as a serum marker in malignant lymphoma.
Epelbaum R; Shalitin C; Segal R; Valansi C; Arselan I; Faraggi D; Leviov M; Ben-Shahar M; Haim N
Pathol Oncol Res; 1998; 4(4):271-6. PubMed ID: 9887357
[TBL] [Abstract][Full Text] [Related]
15. Prognostic markers in malignant lymphoma: an analysis of 1,198 patients treated at a single centre.
Low SE; Horsman JM; Hancock H; Walters SJ; Hancock BW
Int J Oncol; 2001 Dec; 19(6):1203-9. PubMed ID: 11713590
[TBL] [Abstract][Full Text] [Related]
16. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
18. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY.
Avalos BR; Klein JL; Kapoor N; Tutschka PJ; Klein JP; Copelan EA
Bone Marrow Transplant; 1993 Aug; 12(2):133-8. PubMed ID: 8401359
[TBL] [Abstract][Full Text] [Related]
19. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]